Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
AssigneeNeuroSearch A/S
InventorsThomas Varming, Frank Wätjen
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of compounds capable of inhibiting the activity of a proton-gated cation channel in the treatment of alleviation of diseases or disorders associated with, or mediated by a drop in extra cellular pH.
Claims16
A method of inhibiting a mammalian proton-gated ion channel with an isatin derivative represented by the general Formula I
- or a pharmaceutically acceptable salt thereof, wherein
- R1 represents hydrogen, alkyl, phenyl or benzyl;
- and
- X represents oxygen, or a group of the formula NOR2, wherein R2 represents hydrogen, alkyl, acyl, phenyl, or benzyl;
- and
- Y represents a group of the formula N—R4, wherein R4 represents hydrogen, hydroxy or alkyl;
- and
- n is 0;
- and
- R6 represents phenyl, naphthyl, thienyl, or pyridyl all of which groups may be substituted one or more times with halogen, CF3, nitro, amino, cyano, hydroxy, alkyl, alkoxy, phenyl, or a group of the formula —SO2NR′R″, wherein R′ and R″ independently of each other represents hydrogen or alkyl;
- and
- “A” represents ring holding of six atoms, which ring is fused to the benzo-ring at the positions marked “a” and “b”, and formed by one or the following bivalent radicals:
- (a) —NR12—CH2—CH2—CH2— (b),
- (a) —CH2—NR2—CH2—CH2— (b),
- (a) —CH2—CH2—NR12—CH2— (b),
- (a) —CH2—CH2—CH2—NR12 — (b),
- wherein
- R12 represents hydrogen, alkyl, alkyl substituted with hydoxy, alkoxy-alkyl, alkoxy-carbonyl-alkyl, alkyl-carbonyl-oxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, phenyl or benzyl, which phenyl or benzyl group is optionally substituted with halogen, CF3, nitro, amino, cyano, hydroxy-alkyl, alkoxy, or a group of the formula —SO2NR′R″, wherein R′ and R″ independently of each other represents hydrogen or alkyl.
A method for the treatment, prevention or alleviation of a disease, disorder or condition in a subject, which disease, disorder or condition is associated with, or mediated by a drop in extracellular pH, which comprises inhibiting cation channels by administering to the subject a pharmaceutically effective amount of an isatin derivative represented by the general Formula I
- or a pharmaceutically acceptable salt thereof, wherein
- R1 represents hydrogen, alkyl, phenyl or benzyl;
- and
- X represents oxygen, or a group of the formula NOR2, wherein R2 represents hydrogen, alkyl, acyl, phenyl, or benzyl;
- and
- Y represents a group of the formula N—R4, wherein R4 represents hydrogen, hydroxy or alkyl;
- and
- n is 0;
- and
- R6 represents phenyl, naphthyl, thienyl, or pyridyl all of which groups may be substituted one or more times with halogen, CF3, nitro, amino, cyano, hydroxy, alkyl, alkoxy, phenyl, or a group of the formula —SO2NR′R″, wherein R′and R″ independently of each other represents hydrogen or alkyl;
- and
- “A” represents ring holding of six atoms, which ring is fused to the benzo-ring at the positions marked “a” and “b”, and formed by one or the following bivalent radicals:
- (a) —NR12—CH2—CH2—CH2— (b),
- (a) —CH2—NR12—CH2—CH2— (b),
- (a) —CH2—CH2—NR2—CH2— (b),
- (a) —CH2—CH2—CH2—NR12— (b),
- wherein
- R12 represents hydrogen, alkyl, alkyl substituted with hydoxy, alkoxy-alkyl, alkoxy-carbonyl-alkyl, alkyl-carbonyl-oxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, alkynyl, phenyl or benzyl, which phenyl or benzyl group is optionally substituted with halogen, CF3, nitro, amino, cyano, hydroxy-alkyl, alkoxy, or a group of the formula —SO2NR′R″, wherein R′ and R″ independently of each other represents hydrogen or alkyl.
Dependencies are inferred from the claim text.